ML-SI3 is cation channel TRPML inhibitor, with IC50 values of 4.7μM and 1.7μM for TRPML1 and TRPML2, respectively [1]. ML-SI3 binds to the hydrophobic cavity created by S5, S6, and PH1, blocking channel activation of TRPML1 without inhibiting PI(3,5)P2-dependent activation of the channel [2]. ML-SI3 has been widely used to stimulate the secretion of protons by human gastric epithelial cell lines[3].
In vitro, ML-SI3 treatment at 20μM for 24 hours significantly promoted the apoptosis of rat hippocampal neuronal cells and disrupted mitochondrial function[4]. The 75µM ML-SI3 treatment for 24 hours significantly disrupted the epidermal integrity of adult schistosomes[5]. The 24-hour treatment with 10µM ML-SI3 antagonized the peripheral localization of lysosome-associated membrane protein 1 (LAMP1) and fibronectin 1 (FN1) induced by Inositol polyphosphate 4-phosphatase, type II (INPP4B) in BxPC-3 cells[6].
In vivo, ML-SI3 treatment via intraperitoneal injection at a dose of 1.5mg/kg every 2 days for 28 days can protect the myocardial ischemia/reperfusion injury in mice by restoring the autophagy of damaged myocardial cells[7]. ML-SI3 treatment (16mg/kg/day; i.p.) for 3 weeks significantly reversed the inhibitory effect of ML-SA5 (2mg/kg; i.p.) on the lung metastasis of melanoma in mouse model of melanoma[8].
References:
[1] Rühl P, Rosato A S, Urban N, et al. Estradiol analogs attenuate autophagy, cell migration and invasion by direct and selective inhibition of TRPML1, independent of estrogen receptors[J]. Scientific reports, 2021, 11(1): 8313.
[2] Schmiege P, Fine M, Li X. Atomic insights into ML-SI3 mediated human TRPML1 inhibition[J]. Structure, 2021, 29(11): 1295-1302. e3.
[3] Mueller A U, Andersen G, Richter P, et al. Activation of the TRPML1 Ion Channel Induces Proton Secretion in the Human Gastric Parietal Cell Line HGT-1[J]. International Journal of Molecular Sciences, 2024, 25(16): 8829.
[4] Peng T, Xie Y, Zhao S, et al. TRPML1 ameliorates seizures-related neuronal injury by regulating autophagy and lysosomal biogenesis via Ca2+/TFEB signaling pathway[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2024, 1870(8): 167477.
[5] Bais S, Norwillo A, Ruthel G, et al. Schistosome TRPML channels play a role in neuromuscular activity and tegumental integrity[J]. Biochimie, 2022, 194: 108-117.
[6] Saffi G T, Kleine N, Salmena L. The lipid phosphatase INPP4B controls pancreatic cancer cell migration and invasion by regulating fibronectin exocytosis[J]. Journal of Biological Chemistry, 2025: 110716.
[7] Xing Y, Sui Z, Liu Y, et al. Blunting TRPML1 channels protects myocardial ischemia/reperfusion injury by restoring impaired cardiomyocyte autophagy[J]. Basic research in cardiology, 2022, 117(1): 20.
[8] Xing Y, Wei X, Liu Y, et al. Autophagy inhibition mediated by MCOLN1/TRPML1 suppresses cancer metastasis via regulating a ROS-driven TP53/p53 pathway[J]. Autophagy, 2022, 18(8): 1932-1954.
ML-SI3是一种阳离子通道TRPML抑制剂,对TRPML1和TRPML2的IC50值分别为4.7μM和1.7μM[1]。ML-SI3通过结合由S5、S6和PH1结构域形成的疏水空腔,阻断TRPML1的通道激活,且不抑制PI(3,5)P2依赖的通道活化[2]。ML-SI3已广泛应用于刺激人胃上皮细胞系的质子分泌[3]。
在体外,使用20μM的ML-SI3处理大鼠海马神经元细胞24小时,能显著促进细胞凋亡并破坏线粒体功能[4]。用75µM的ML-SI3处理成年血吸虫24小时,可显著破坏表皮完整性[5]。以10µM的ML-SI3处理BxPC-3细胞24小时,能拮抗Inositol polyphosphate 4-phosphatase, type II(INPP4B)诱导的溶酶体相关膜蛋白1(LAMP1)和纤连蛋白1(FN1)的外周定位[6]。
在体内,每两天腹腔注射1.5mg/kg剂量的ML-SI3连续28天,可通过恢复受损心肌细胞的自噬保护小鼠心肌缺血/再灌注损伤[7]。每日腹腔注射16mg/kg剂量的ML-SI3连续3周,可显著逆转ML-SA5(2mg/kg; i.p.)在黑色素瘤小鼠模型中对黑素瘤肺转移的抑制作用[8]。
















